 LA JOLLA, Calif., May 13, 2021 GLOBE NEWSWIRE -- Equillium, Inc. Nasdaq: EQ, a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease aGVHD has been accepted for oral presentation at EHA2021 Virtual Congress. The annual meeting of the European Hematology Association will be held virtually June 9 17, 2021. 